Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement

Bruton’s tyrosine kinase (BTK) is a clinically validated target for B-cell leukemias and lymphomas with FDA-approved small-molecule inhibitors ibrutinib and acalabrutinib. Tirabrutinib (GS-4059/ONO-4059, Gilead Sciences, Inc., Foster City, CA) is a second-generation, potent, selective, irreversible...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:SLAS Discov
Main Authors: Yu, Helen, Truong, Hoa, Mitchell, Scott A., Liclican, Albert, Gosink, John J., Li, Wanying, Lin, Julie, Feng, Joy Y., Jürgensmeier, Juliane M., Billin, Andrew, Xu, Ren, Patterson, Scott, Pagratis, Nikos
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151956/
https://ncbi.nlm.nih.gov/pubmed/30011241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2472555218786165
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados